Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization

Archives of Pharmacal Research

Volumn 36, Issue 8, 2013, Pages 981-992

  Dehghan, S ^a   Kheiri, M Tavassoti ^b   Tabatabaiean, M ^b   Darzi, S ^b   Tafaghodi, M ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Chitosan nanospheres; CpG ODN; Influenza; Nasal immunization; Quillaja Saponin

Indexed keywords

CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; NANOSPHERE; QUILLAJA SAPONIN; TRIPOLYPHOSPHATE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRY POWDER; GELATION; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFRARED SPECTROSCOPY; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; SURFACE PROPERTY; VIRUS INACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; NANOSPHERES; POWDERS;

EID: 84881311910     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0043-4     Document Type: Article

References (74)

1. Alley, M.C.; D.A. Scudiero, A. Monks, M.L. Hursey, M.J. Czerwinski, D.L. Fine, B.J. Abbott, J.G. Mayo, R.H. Shoemaker, and M.R. Boyd. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Research 48: 589-601.
2. Amidi, M.; E. Mastrobattista, W. Jiskoot, and W.E. Hennink. 2010. Chitosan-based delivery systems for protein therapeutics and antigens. Advanced Drug Delivery Reviews 62: 59-82.
3. Amorij, J.P.; A. Huckriede, J. Wilschut, H.W. Frijlink, and W.L. Hinrichs. 2008. Development of stable influenza vaccine powder formulations: Challenges and possibilities. Pharmaceutical Research 25: 1256-1273.
4. Amour, S.; N. Voirin, C. Regis, M. Bouscambert-Duchamp, B. Comte, B. Coppéré, S. Pires-Cronenberger, B. Lina, and P. Vanhems. 2012. Influenza vaccine effectiveness among adult patients in a University of Lyon hospital (2004-2009). Vaccine 30: 821-824.
5. Arthanari, S.; P. Renukadevi, and K.R. Mani. 2011. Preparation and evaluation of sucrose stabilized tetanus toxoid encapsulated into chitosan microspheres. Genomic Medicine, Biomarkers, and Health Sciences 3: 91-97.
6. Artursson, P.; T. Lindmark, S.S. Davis, and L. Illum. 1994. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharmaceutical Research 11: 1358-1361.
7. Asanuma, H.; N.B. Zamri, S. Sekine, Y. Fukuyama, D. Tokuhara, R.S. Gilbert, T. Fukuiwa, K. Fujihashi, T. Sata, and M. Tashiro. 2012. A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine 30: 803-812.
8. Baia, M.; S. Astilean, and T. Iliescu. 2008. Fundamentals of infrared and Raman spectroscopy, SERS, and theoretical simulations. Raman and SERS investigations of pharmaceuticals, 9-35. Berlin: Springer.
9. Banerjee, T.; S. Mitra, A. Kumar Singh, R. Kumar Sharma, and A. Maitra. 2002. Preparation, characterization and biodistribution of ultrafine chitosan nanoparticles. International Journal of Pharmaceutics 243: 93-105.
10. Bernkop-Schnürch, A.; and M.E. Krajicek. 1998. Mucoadhesive polymers as platforms for peroral peptide delivery and absorption: Synthesis and evaluation of different chitosan-EDTA conjugates. Journal of Control Release 50: 215-223.
11. Bollag, D.M.; M.D. Rozycki, and S.J. Edelstein. 1996. Protein methods. Wiley-Liss: New York.
12. Boonsongrit, Y.; B.W. Mueller, and A. Mitrevej. 2008. Characterization of drug-chitosan interaction by 1H NMR, FTIR and isothermal titration calorimetry. European Journal of Pharmaceutics and Biopharmaceutics 69: 388-395.
13. Buendia, A.J.; L. Nicolas, N. Ortega, M.C. Gallego, C.M. Martinez, J. Sanchez, M.R. Caro, J.A. Navarro, and J. Salinas. 2007. Characterization of a murine model of intranasal infection suitable for testing vaccines against C. abortus. Veterinary Immunology and Immunopathology 115: 76-86.
14. Carcaboso, A.M.; R.M. Hernandez, M. Igartua, J.E. Rosas, M.E. Patarroyo, and J.L. Pedraz. 2004. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22: 1423-1432.
15. Carter, J.B.; and V.A. Saunders. 2007. Virology, principles and applications. Toronto: Wiley.
16. Choisnard, L.; A. Geze, M. Bigan, J.L. Putaux, and D. Wouessidjewe. 2005. Efficient size control of amphiphilic cyclodextrin nanoparticles through a statistical mixture design methodology. Journal of Pharmacy & Pharmaceutical Sciences 8: 593-601.
17. Chowdhury, D.K.; and A.K. Mitra. 2000. Kinetics of a model nucleoside (guanosine) release from biodegradable poly(DL-lactide-co-glycolide) microspheres: a delivery system for long-term intraocular delivery. Pharmaceutical Development and Technology 5: 279-285.
18. Dehghan, S.; R. Aboofazeli, M. Avadi, and R. Khaksar. 2010. Formulation optimization of nifedipine containing microspheres using factorial design. African Journal of Pharmacy and Pharmacology 4: 346-354.
19. Fernandez-Urrusuno, R.; P. Calvo, C. Remunan-Lopez, J.L. Vila-Jato, and M.J. Alonso. 1999. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharmaceutical Research 16: 1576-1581.
20. Gan, Q.; and T. Wang. 2007. Chitosan nanoparticle as protein delivery carrier - Systematic examination of fabrication conditions for efficient loading and release. Colloids and Surfaces B: Biointerfaces 59: 24-34.
21. Garmise, R.J.; H.F. Staats, and A.J. Hickey. 2007. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 8: E81.
22. Ghadiri, M.; S. Fatemi, A. Vatanara, D. Doroud, A.R. Najafabadi, M. Darabi, and A.A. Rahimi. 2012. Loading hydrophilic drug in solid lipid media as nanoparticles: Statistical modeling of entrapment efficiency and particle size. International Journal of Pharmaceutics 424: 128-137.
23. Gremlich, H.-U. 2000. Infrared and Raman spectroscopy. In Analytical techniques in combinatoral chemistry, ed. M.E. Swartz, 65-76. New York: Marcel Dekker.
24. Gupta, N.K.; P. Tomar, V. Sharma, and V.K. Dixit. 2011. Development and characterization of chitosan coated poly-(varepsilon-caprolactone) nanoparticulate system for effective immunization against influenza. Vaccine 29: 9026-9037.
25. Hagenaars, N.; R.J. Verheul, I. Mooren, P.H. De Jong, E. Mastrobattista, H.L. Glansbeek, J.G. Heldens, H. Van Den Bosch, W.E. Hennink, and W. Jiskoot. 2009. Relationship between structure and adjuvanticity of N, N, N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. Journal of Control Release 140: 126-133.
26. Iqbal, M.; W. Lin, I. Jabbal-Gill, S.S. Davis, M.W. Steward, and L. Illum. 2003. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine 21: 1478-1485.
27. Jayakumar, R.; M. Prabaharan, and R.A.A. Muzzarelli. 2011. Chitosan for biomaterials I. Berlin: Springer.
28. Kaufmann, S.H.E. 2004. Novel vaccination strategies. Weinheim: Wiley-VCH.
29. Khatri, K.; A.K. Goyal, P.N. Gupta, N. Mishra, and S.P. Vyas. 2008. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. International Journal of Pharmaceutics 354: 235-241.
30. Kim, T.H.; Y.H. Park, K.J. Kim, and C.S. Cho. 2003. Release of albumin from chitosan-coated pectin beads in vitro. International Journal of Pharmaceutics 250: 371-383.
31. Krieg, A.M.; A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
32. Kuilin, D.; Z. Yaqin, J. Na, L. Jing, Z. Xiangyang, and T.A. Hua. 2007. A dithiocarbonate group-assisted graft copolymerization of methyl acrylate onto chitosan. Chemical Journal on Internet. Avaliable at: http://www.chemistrymag. org/cji/2007/094019pe.htm.
33. Liang, J.; F. Li, Y. Fang, W. Yang, X. An, L. Zhao, Z. Xin, L. Cao, and Q. Hu. 2011. Synthesis, characterization and cytotoxicity studies of chitosan-coated tea polyphenols nanoparticles. Colloid Surface B 82: 297-301.
34. Limapornvanich, A.; S. Jitpukdeebodintra, C. Hengtrakool, and U. Kedjarune-Leggat. 2009. Bovine serum albumin release from novel chitosan-fluoro-aluminosilicate glass ionomer cement: Stability and cytotoxicity studies. Journal of Dentistry 37: 686-690.
35. Liu, Y.; Y. Sun, Y. Li, S. Xu, J. Tang, J. Ding, and Y. Xu. 2011. Preparation and characterization of α-galactosidase-loaded chitosan nanoparticles for use in foods. Carbohydrate Polymers 83: 1162-1168.
36. Longo-Sorbello, G.S.A.; G. Saydam, D. Banerjee, and J.R. Bertino. 2005. Cytotoxicity and cell growth assays. In Cell biology, ed. J.E. Celis, N. Carter, K. Simons, J.V. Small, and T. Hunter, 315-324. Burlington: Elsevier.
37. Lopez, A.M.; R. Hecker, G. Mutwiri, S.V.D. Littel-Van Den Hurk, L.A. Babiuk, and H.G.G. Townsend. 2006. Formulation with CpG ODN enhances antibody responses to an equine influenza virus vaccine. Veterinary Immunology and Immunopathology 114: 103-110.
38. Lu, W.; and T.G. Park. 1995. Protein release from poly(lactic-co-glycolic acid) microspheres: protein stability problems. PDA Journal of Pharmaceutical Science and Technology 49: 13-19.
39. Lueßen, H.L.; C.O. Rentel, A.F. Kotzé, C.M. Lehr, A.G. De Boer, J.C. Verhoef, and H.E. Junginger. 1997. Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. Journal of Controlled Release 45: 15-23.
40. Malyala, P.; D.T. O'hagan, and M. Singh. 2009. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Advanced Drug Delivery Reviews 61: 218-225.
41. Mao, S.; W. Sun, and T. Kissel. 2010. Chitosan-based formulations for delivery of DNA and siRNA. Advanced Drug Delivery Reviews 62: 12-27.
42. Matassov, D.; A. Cupo, and J.M. Galarza. 2007. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunology 20: 441-452.
43. Mehrgan, H.; and S.A. Mortazavi. 2005. The release behavior and kinetic evaluation of diltiazem HCl from various hydrophilic and plastic based matrices. Iranian Journal of Pharmaceutical Research 3: 137-146.
44. Mimaki, Y.; M. Kuroda, A. Kameyama, A. Yokosuka, and Y. Sashida. 1998. Steroidal saponins from the rhizomes of Hosta sieboldii and their cytostatic activity on HL-60 cells. Phytochemistry 48: 1361-1369.
45. Mohajel, N.; A.R Najafabadi, K. Azadmanesh, A. Vatanara, E. Moazeni, A. Rahimi and K. Gilani. 2012. Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. International Journal of Pharmaceutics 423: 577-585.
46. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods 65: 55-63.
47. Motwani, S.K.; S. Chopra, S. Talegaonkar, K. Kohli, F.J. Ahmad, and R.K. Khar. 2008. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: Formulation, optimisation and in vitro characterisation. European Journal of Pharmaceutics and Biopharmaceutics 68: 513-525.
48. Nagai, T.; Y. Suzuki, H. Kiyohara, E. Susa, T. Kato, T. Nagamine, Y. Hagiwara, S.-I. Tamura, T. Yabe, C. Aizawa, and H. Yamada. 2001. Onjisaponins, from the root of Polygala tenuifolia Willdenow, as effective adjuvants for nasal influenza and diphtheria-pertussis-tetanus vaccines. Vaccine 19: 4824-4834.
49. O'hagan, D. 2006. Microparticles as vaccine delivery systems. In Immunopotentiators in modern vaccines, ed. V. Schijins, and D. O'hagan, 123-147. USA: Academic Press.
50. Oxford, J.S.; T. Corcoran, and A.L. Hugentobler. 1981. Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. Journal of Biological Standardization 9: 483-491.
51. Palmer, J.S.; W.J. Cromie, and R.C. Lee. 1998. Surfactant administration reduces testicular ischemia-reperfusion injury. Journal of Urology 159: 2136-2139.
52. Peterson, G.L. 1977. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Analytical Biochemistry 83: 346-356.
53. Poovi, G.; U.M. Dhana Lekshmi, N. Narayanan, and P. Neelakanta Reddy. 2011. Preparation and characterization of repaglinide loaded chitosan polymeric nanoparticles. Research Journal of Nanoscience and Nanotechnology 1: 12-24.
54. Qi, L.; and Z. Xu. 2006. In vivo antitumor activity of chitosan nanoparticles. Bioorganic & Medicinal Chemistry Letters 16: 4243-4245.
55. Read, R.C.; S.C. Naylor, C.W. Potter, J. Bond, I. Jabbal-Gill, A. Fisher, L. Illum, and R. Jennings. 2005. Effective nasal influenza vaccine delivery using chitosan. Vaccine 23: 4367-4374.
56. Rejinold, N.S.; M. Muthunarayanan, K. Muthuchelian, K.P. Chennazhi, S.V. Nair, and R. Jayakumar. 2011. Saponin-loaded chitosan nanoparticles and their cytotoxicity to cancer cell lines in vitro. Carbohydrate Polymers 84: 407-416.
57. Revaz, V.; R. Zurbriggen, C. Moser, J.T. Schiller, F. Ponci, M. Bobst, and D. Nardelli-Haefliger. 2007. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Research 76: 75-85.
58. Sarmento, B.; D. Ferreira, F. Veiga, and A. Ribeiro. 2006. Characterization of insulin-loaded alginate nanoparticles produced by ionotropic pre-gelation through DSC and FTIR studies. Carbohydrate Polymers 66: 1-7.
59. Sayin, B.; S. Somavarapu, X.W. Li, D. Sesardic, S. Senel, and O.H. Alpar. 2009. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines. European Journal of Pharmaceutical Sciences 38: 362-369.
60. Scudiero, D.A.; R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, T.H. Nofziger, M.J. Currens, D. Seniff, and M.R. Boyd. 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Research 48: 4827-4833.
61. Siepmann, J.; and N.A. Peppas. 2011. Higuchi equation: Derivation, applications, use and misuse. International Journal of Pharmaceutics 418: 6-12.
62. Skene, C.D.; and P. Sutton. 2006. Saponin-adjuvanted particulate vaccines for clinical use. Methods 40: 53-59.
63. Soppimath, K.S.; A.R. Kulkarni, and T.M. Aminabhavi. 2001. Encapsulation of antihypertensive drugs in cellulose-based matrix microspheres: Characterization and release kinetics of microspheres and tableted microspheres. Journal of Microencapsulation 18: 397-409.
64. Sun, H.-X.; Y. Xie, and Y.-P. Ye. 2009. Advances in saponin-based adjuvants. Vaccine 27: 1787-1796.
65. Tafaghodi, M.; M. Eskandari, M. Kharazizadeh, A. Khamesipour, and M.R. Jaafari. 2010. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins. Tropical Biomedicine 27: 639-650.
66. Tafaghodi, M.; and S. Rastegar. 2010. Preparation and in vivo study of dry powder microspheres for nasal immunization. Journal of Drug Targeting 18: 235-242.
67. Van Der Lubben, I.M.; G. Kersten, M.M. Fretz, C. Beuvery, J. Coos Verhoef, and H.E. Junginger. 2003. Chitosan microparticles for mucosal vaccination against diphtheria: Oral and nasal efficacy studies in mice. Vaccine 21: 1400-1408.
68. Van Der Lubben, I.M.; J.C. Verhoef, G. Borchard, and H.E. Junginger. 2001a. Chitosan and its derivatives in mucosal drug and vaccine delivery. European Journal of Pharmaceutical Sciences 14: 201-207.
69. Van Der Lubben, I.M.; J.C. Verhoef, G. Borchard, and H.E. Junginger. 2001b. Chitosan for mucosal vaccination. Advanced Drug Delivery Reviews 52: 139-144.
70. Vila, A.; A. Sánchez, K. Janes, I. Behrens, T. Kissel, J.L.V. Jato, and M.A.J. Alonso. 2004. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. European Journal of Pharmaceutics and Biopharmaceutics 57: 123-131.
71. Wan, A.; Y. Sun, and H. Li. 2009. Characterization of novel quaternary chitosan derivative nanoparticles loaded with protein. Journal of Applied Polymer Science 114: 2639-2647.
72. WHO, WHO media influenza factsheet, Geneva, (2003).
73. Xu, Y.; and Y. Du. 2003. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. International Journal of Pharmaceutics 250: 215-226.
74. Yuan, X.; B.A. Shah, N.K. Kotadia, J. Li, H. Gu, and Z. Wu. 2010. The development and mechanism studies of cationic chitosan-modified biodegradable PLGA nanoparticles for efficient siRNA drug delivery. Pharmaceutical Research 27: 1285-1295.